Systemic lupus erythematosus (SLE)
Irene Blanco, MD, MS
Northwestern University
Chicago, IL, United States
Disclosure(s): UCB: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing)
.png "Saira Sheikh, MD photo")
Saira Sheikh, MD
Linda Coley Sewell Distinguished Professor of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States
Disclosure(s): AstraZeneca: Consultant (Terminated, October 7, 2022); Aurinia Pharmaceuticals Inc.: Consultant (Terminated, September 18, 2021); Biogen: Consultant (Terminated, August 24, 2022); GSK: Advisor or Review Panel Member (Ongoing); Lilly USA: Consultant (Terminated, November 19, 2021); Pfizer: Grant/Research Support (Terminated, January 1, 2022)
Lupus is more prevalent in women and certain racial/ethnic groups, namely African American and Latino patients. Patients from these groups also tend to have worse disease outcomes. Despite this, African American and Latino women are often underrepresented in clinical trials, which in turn leads to lack of information on key aspects of new therapies. There are many strategies that have been evaluated to increase minority participation in clinical trials. This session will review the data on barriers at both the patient and physician level and proposed interventions to increase minority participation in clinical trials.
Speaker: Saira Sheikh, MD – University of North Carolina at Chapel Hill
Speaker: Irene Blanco, MD, MS – Northwestern University
